ClinicalTrialsFinder

RCB Classification 1-2 Clinical Trials in Guangzhou

1 recruitingGuangzhou, China

Showing 1–1 of 1 trials

Recruiting
Phase 3

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

HER2-positive Breast CancerEarly Stage Breast CancerAdjuvant Treatment After Trastuzumab+2 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University300 enrolled1 locationNCT05760612